Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 06/23/2025 at 15:00, 10 months 17 days ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding

Crofelemer Jaguar Health Phase 2 Study MVID Intestinal Failure
BRIEF

published on 06/17/2025 at 15:05, 10 months 23 days ago

Jaguar Health participera à la conférence Emerging Growth

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Conférence Sur La Croissance Émergente
BRIEF

published on 06/17/2025 at 15:05, 10 months 23 days ago

Jaguar Health to Present at Emerging Growth Conference

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference
PRESS RELEASE

published on 06/17/2025 at 15:00, 10 months 23 days ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRIEF

published on 06/11/2025 at 16:05, 10 months 29 days ago

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 06/11/2025 at 16:05, 10 months 29 days ago

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
PRESS RELEASE

published on 06/11/2025 at 16:00, 10 months 29 days ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 11 months ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
BRIEF

published on 06/09/2025 at 22:20, 11 months ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
PRESS RELEASE

published on 06/09/2025 at 22:15, 11 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population

Accesswire

Published on 05/09/2026 at 01:55, 1 day 20 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 20 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 20 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 22 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 23 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 6 hours 4 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 8 hours 9 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 10 hours 24 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 3 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 1 hour ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 2 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 2 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 3 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 3 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 3 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE